Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab - The U.S. FDA has informed UCB via letter that the Agency was unable to complete review of the BLA for bimekizumab by the PDUFA date and is deferring action on the application - The Agency cite...
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress -- Interim results from the BE BRIGHT open-label extension study showed clinical responses observed in bimekizumab-treated patients...
UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older - Tablets, oral solution, and IV (or intravenous) dosage forms of BRIVIACT® (brivaracetam) CV now FDA-approved as both monotherap...
UCB SA (UCBJF) Q2 2021 Results Conference Call July 29, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl - E...
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis - Today, two manuscripts published back to back detail the full results from the BE RADIANT and BE SURE studies, comparing the efficacy and safety ...
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 PR Newswire BRUSSELS , April 23, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 12 abstracts on bimekizumab, an investigational IL-17A and IL-17F inhibitor, in the...
UCB SA (UCBJF) Q4 2020 Results Conference Call February 25, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl...
The following slide deck was published by UCB SA in conjunction with their 2020 Q4 earnings call. For further details see: UCB SA 2020 Q4 - Results - Earnings Call Presentation
UCB Full Year Report 2020: UCB - sustaining growth, now and into the future · Revenue increased to € 5.3 billion (+9%, +8% CER[1]) net sales to € 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was € 1.4 billion (+1%, -4%...
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...